VIRIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:36):

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response...

Stats
本日の出来高	44 579.00
平均出来高	301 203
時価総額	8.86M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.0800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.640
ATR14	$0.00800 (1.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-26	Pridgen William	Buy	2 917	Stock Option (right to buy)
2024-02-26	Thomas John C	Buy	4 167	Stock Option (right to buy)
2024-02-26	Whitley Richard James	Buy	4 000	Stock Option (right to buy)
2024-02-26	Keefer David R	Buy	4 709	Stock Option (right to buy)
2024-02-26	Burch Richard Alan	Buy	2 917	Stock Option (right to buy)

INSIDER POWER
99.86
Last 92 transactions
Buy: 2 833 595 \| Sell: 299 106

ボリューム相関

長: 0.07 (neutral)

短: 0.56 (weak)

Signal:(52.408) Neutral

Virios Therapeutics, LLC 相関

10 最も正の相関
BOCH	0.83
RDI	0.814
SHSP	0.814

10 最も負の相関
GLPG	-0.857
GAINL	-0.804

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Virios Therapeutics, LLC 相関 - 通貨/商品

0.19
( neutral )

0.21
( neutral )

0.00
( neutral )

-0.14
( neutral )

Virios Therapeutics, LLC 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.280

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.280

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.100

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Virios Therapeutics, LLC

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.